Adiponectin and Ethnic Differences in Insulin Resistance

Type 2 Diabetes Clinical Trial

Official title:

Adiponectin as an Independent Determinant of Ethnic Differences in Insulin Resistance

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01831102
• Other study ID #: 10-1260
• Status: Completed
• Phase: N/A
• First received: April 5, 2013
• Last updated: April 9, 2013
• Start date: March 2011
• Est. completion date: August 2011

Study information

• Verified date: April 2013
• Source: University of Colorado, Denver
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this protocol is to measure and compare levels of the circulating protein adiponectin and adiponectin's association with insulin sensitivity in Mexican Americans and non-Latino white subjects. The investigators also aimed to examine associations between nutritional factors and adiponectin levels.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: August 2011
• Est. primary completion date: August 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• 18-60 years of age

• BMI 20.0-34.9 m/kg2

• Mexican American with at least 3 grandparents born in Mexico or white with no grandparents of Latino descent.

Exclusion Criteria:

• pregnancy

• breastfeeding

• diabetes mellitus

• blood pressure > 160/100 mmHg

• creatinine > 1.5 mg/dl or glomerular filtration rate (GFR) < 60

• liver function tests > 3x upper limit of normal (ULN)

• h/o heart failure

• h/o eating disorder

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Insulin Resistance
• Type 2 Diabetes

Intervention

Other:
• none- observational study

Locations

Country	Name	City	State
United States	University of Colorado Anschutz Medical Center	Aurora	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	total adiponectin concentration		measured once during second study visit, in fasting condition	No
Secondary	Insulin sensitivity	Calculated from insulin and glucose values obtained during IV glucose tolerance test.	Measured once, during second study visit.	No